Kroger reports strong earnings and stock performance, including a CEO shake-up.
From Nasdaq: 2025-03-14 12:55:00
Kroger reported earnings with a 2.4% increase in identical sales and over $1.4 billion in operating profit from alternative profit businesses. Digital sales saw a 10% growth, highlighting the importance of convenience in the retail space. After a failed merger with Albertsons, Kroger returned $5 billion to shareholders through a share repurchase program, boosting stock performance to an all-time high. The departure of CEO Rodney McMullen was not addressed directly, potentially due to legal implications surrounding his resignation forfeiting $11.2 million in compensation. Kroger’s stock has risen 12% following the Albertsons deal block in December due to market uncertainty. With flat earnings and profit, Kroger aims for 8-11% total shareholder return. Abercrombie & Fitch’s sales forecast disappointed, with slower growth in the fourth quarter. While sales at Abercrombie brand grew just 2%, Hollister sales jumped 16%. Full year 2025 guidance shows slower growth than expected, with a predicted 3-5% increase in consolidated sales. Tariff impact on Abercrombie is around $5 million, with a focus on US and Canada sales. Inventory has increased by $100 million, signaling possible challenges ahead. Consumer confidence is at an all-time low due to uncertainty around tariffs, impacting retailers like Abercrombie & Fitch. The company faced inventory concerns and failed to transition to the spring line smoothly, raising questions about consumer resonance. Abercrombie & Fitch’s valuation metrics have dropped significantly, leading to doubts about its growth potential. Turning Point Brands is seeing growth from Farm Bill compliant hemp products and ALP Nicotine Pouches, tapping into markets where cannabis is not yet legalized. Modern oral nicotine products, like ALP, are driving growth for Turning Point Brands, showcasing potential for the company. Turning Point Brands reported $11.2 million in modern oral revenue in Q4, with a projected revenue of $60-$80 million by 2025. This growth is driven by triple-digit growth rates in Nicotine pouch products and new retail partnerships. The company sees opportunities in the green wave and zig zag segment for further growth. Additionally, cross-selling opportunities exist with retailers selling nicotine pouches and legal hemp products. The company aims to accelerate growth in the growing market, which is expected to grow at a rate of 30% through the end of the decade.
Intuitive Surgical’s da Vinci Surgical System allows surgeons to operate remotely with precision and flexibility. The system is used in urology, gynecology, and general surgery procedures, offering benefits like less blood loss and quicker recovery times. The company’s EyeOn platform specializes in minimally invasive bronchoscopy for lung biopsies in cancer patients. Intuitive Surgical’s development of separate robotic systems for different surgeries reflects the need for specialized tools for different procedures. Intuitive Surgical’s da Vinci robot has evolved over 25 years, originally funded by DARPA for remote surgical systems and cardiac procedures, but now mainly used for other surgeries. The latest model, da Vinci 5, includes force feedback for surgeons. The company is exploring the EyeOn platform for catheter-based procedures. Despite competition, Intuitive spends nearly 14% of revenue on R&D, staying ahead of emerging systems from competitors like Verb Surgical and Medtronic. By retaining top engineering talent, Intuitive Surgical aims to maintain its dominance in the industry. Intuitive Surgical has top-notch management, including original system designer Gary Guthart. The company rewards employees generously with stock-based compensation, leading to a rising stock price. Medical devices like Da Vinci undergo FDA approval through PMA or 510(k) pathways. Da Vinci’s approvals via 510(k) make it easier to introduce incremental innovations. Other companies face a tougher PMA pathway for their systems. Intuitive Surgical benefits from its approval history. The Motley Fool reminds investors to make decisions based on personal research, not solely on program recommendations. Full disclosure of author positions and affiliations is provided.
Read more at Nasdaq: Kroger CEO Shake-Up | Nasdaq